Prospective Evaluation of the Eyeball Test for Assessing Frailty in Elderly Patients with Valvular Heart Disease
|
|
- Gillian McKenzie
- 5 years ago
- Views:
Transcription
1 Prospective Evaluation of the Eyeball Test for Assessing Frailty in Elderly Patients with Valvular Heart Disease Background Frailty is a common occurrence in elderly patients Approximately half of the patients being screened for transcatheter valve therapies are frail Cardiac surgical risk scores and subjective clinical assessments guide whether patients are evaluated for transcatheter valve therapies vs. surgery Cardiac Risk Scores do not take frailty into account Frailty assessment of TAVR candidates to date has been mainly based on the traditional eyeball test 1
2 Significance Increasing use of transcatheter aortic valve replacement (TAVR) in the treatment of elderly high-risk patients with aortic stenosis The less-invasive nature of TAVR is bringing more of these patients into the clinic for evaluation and therapy Frailty There is no accepted definition of frailty nor a consensus about specific clinical measures or laboratory markers for its diagnosis There is extensive overlap and interactions between disability, comorbidity, and frailty The most commonly used definition of frailty is based on the criteria of Fried et al., which assess up to 5 domains: 1. Nutritional status (weight loss) 2. Energy (exhaustion) 3. Physical activity (leisure time activity) 4. Mobility (gait speed) 5. Strength (grip strength) 2
3 Previous Study Green et al. assessed frailty in 159 patients who received TAVR as part of the PARTNER (Placement of AoRTic TraNscathetER Valve Trial) 4 factors were measured pre-tavr: gait speed with a 15-ft timed walk test, weakness by dominant hand-grip strength test, decline in independence in ADL, and serum albumin for malnutrition and wasting Green et al. derived a frailty score, where highest (maximum score = 12) represented the most frail and lowest score represented the least frail in their cohort. The mortality rate at 1-year follow-up was as low as 3% among patients with low frailty scores, as compared with 13% among patients with high frailty scores Study Objective To determine the incremental utility of objective criteria for frailty assessment 3
4 Patient Population Age 18 yrs Willing and capable of signing informed consent Patient undergoing routine clinical evaluation at Minneapolis Heart Institute (MHI) Patient has diagnosis of valvular heart disease or coronary artery disease, and is being considered for percutaneous or surgical interventional procedure (e.g., percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), valve replacement) Data Analysis Providers examined each patient and independently graded frailty with a Likert scale (1 to 7, with 7 being most frail) and assessed surgical risk (low, intermediate, high, prohibitive) Each patient underwent prospective, objective measurement of frailty with assessments of 15-foot and 6-min walk times, handgrip strength, activities of daily living (Katz index), and SF-12 quality-of-life Providers were informed of the objective frailty data, and were asked to re-grade frailty 4
5 Results Frailty scores on the Likert scale decreased (i.e., less frailty) once the provider became aware of the objective data (3.7±2.0 vs. 3.4±2.0; p=0.003) For the binary classification of frailty (i.e., frail or not), the net reclassification rate after awareness of the objective data was 41%. A change of 2 points on the Likert scale occurred in 22% Handgrip strength was the most common objective measure used for net reclassification Overall, reclassification of surgical risk occurred in 26% of patients with awareness of objective frailty measures Baseline Assessment N=101 Passed Handgrip strength assessment Failed Handgrip strength assessment Frail Not Frail Total incorrect: 56 Baseline Assessment N=101 Passed Katz ADL assessment Failed Katz ADL assessment Frail 41 8 Not Frail 50 1 Total incorrect: 42 Baseline Assessment N=101 Passed 15 Foot Walk Failed 15 Foot Walk Frail Not Frail 48 3 Total incorrect: 24 5
6 Conclusions The eyeball test was insufficient for assessing frailty in ~40% of elderly patients being considered for surgery In addition to physical status, other domains such as cognitive ability, mood, and mental health should be considered to obtain a more complete assessment of frailty Objective frailty measures should be routinely considered in the assessment of these patients, and further study on their incremental value for risk prognostication is needed References 1. Mack M. Frailty and aortic valve disease.j Thorac Cardiovasc Surg Mar;145(3 Suppl):S Afilalo J. Frailty in patients with cardiovascular disease: Why, when, and how to measure. Curr Cardiovasc Risk Rep 2011;5:467: Bergman H, Ferrucci L, Guralnik J, et al. Frailty: an emerging research and clinical paradigm- issues and controversies. J Gerontol A Biol Scie Med Sci 2007;62: Katz S. Assessing self-maintenance: Activities of daily living, mobility, and instrumental activities of daily living. J Am Geriatr Soc 1983;31: Fried L.P., Tangen C.M., Walston J., Frailty in older adults: evidence for a phenotype. J Gerontol Med Sci. 2001;56A:M146-M Rodés-Cabau J, Mok M. Working Toward a Frailty Index in Transcatheter Aortic Valve Replacement: A Major Move Away From the Eyeball Test. J Am Coll Cardiol Intv. 2012;5(9): Green P, Woglom AE, Genereux P, et al. The impact of frailty status on survival after transcatheter aortic valve replacement in older adults with severe aortic stenosis: a single-center experience. J Am Coll Cardiol Intv 2012;9:
7 Acknowledgements Paul Sorajja, MD Lisa Tindell Melissa Buescher MHI clinic staff MHIF research staff QUESTIONS? 7
8 All patients N=101 Age (yr) 76.8 ±13.8 Men no. (%) 60 (60) Hypertension no. (%) 89 (89) Diabetes no. (%) 29 (29) Atrial fibrillation no. (%) 54 (54) COPD no. (%) 18 (18) O 2 -dependent 3 (3) CAD no. (%) 58 (58) Prior PCI no. (%) 37 (37) Prior CABG no. (%) 19 (19) >1 prior sternotomy 5 (5) ICD no. (%) 3 (3) PPM no. (%) 8 (8) BMI 28.7 ±6.6 Creatinine g/dl 1.1 ±0.5 LVEF (%) 58 ±12 Left ventricular hypertrophy 27 (27) Moderate or severe AS no. (%) 41 (41) Moderate or severe MR no. (%) 30 (30) Other valvular disease no (%) 29 (29) STS-PROM (%) 5.2 ±3.8 8
Interventions in the Elderly
Interventions in the Elderly Satya Reddy Atmakuri MD FIFTH ANNUAL SYMPOSIUM I Have No Financial Interest to Disclose People greater than 65 years of age will increase from 12% of population in 2000 to
More informationValve Replacement without a Scalpel Transcatheter Aortic Valve Replacement (TAVR) Charles T. Klodell, M.D.
Valve Replacement without a Scalpel Transcatheter Aortic Valve Replacement (TAVR) Charles T. Klodell, M.D. Professor, Thoracic and Cardiovascular Surgery University of Florida klodell@surgery.ufl.edu Disclosures
More informationNeal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute
Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute Despite a 33 fold growth in the first five years, there is still tremendous variability among penetration in different countries
More informationRISK PREDICTION IN TAVR. Beyond STS PROM and the Eyeball Assessment
RISK PREDICTION IN TAVR Beyond STS PROM and the Eyeball Assessment SAVR VS TAVR BIOPROSHETIC OPEN SURGICAL VALVE (SAVR) BIOPROSTHETIC TRANSCATHETER VALVE (TAVR) This Photo by Unknown Author is licensed
More informationPre- Cardiac intervention. Dr. Victor Sim 26 th Sept 2014
Pre- Cardiac intervention Frailty assessment Dr. Victor Sim 26 th Sept 2014 Defining frailty Lacks consensus (Rockwood CMAJ 2005;173(5):489-95 Introduction) Some consider symptoms, signs, diseases and
More informationAgeing and frailty Facts and myths. Finn Rønholt MD. Ph.d. MPA.
Ageing and frailty Facts and myths Finn Rønholt MD. Ph.d. MPA. Ageing and frailty Facts and myths Ageing Ageing and disease Ageing and frailty Risk scores Physical activity and rehabilitation Most common
More informationMeasuring the risk in valve patients Lessons learnt from the TAVI story? Bernard Iung Bichat Hospital, Paris, France
Measuring the risk in valve patients Lessons learnt from the TAVI story? Bernard Iung Bichat Hospital, Paris, France Faculty disclosure Bernard Iung I disclose the following financial relationships: Consultant
More informationFrailty Assessment: Simplifying the Complex
Frailty Assessment: Simplifying the Complex Natalie Sanders, DO Internal Medicine, Geriatrics Rocky Mountain Geriatrics Conference 2017 U N I V E R S I T Y O F U T A H H E A L T H, 2 0 1 7 OBJECTIVES Define
More informationPre- Cardiac intervention. Dr. Victor Sim 16 th Oct 2014
Pre- Cardiac intervention Frailty assessment Dr. Victor Sim 16 th Oct 2014 Topics to cover Defining frailty Pathophysiology of frailty Are current pre-cardiac surgery assessment tools adequate? Why do
More information2/15/2018 DISCLOSURES OBJECTIVES. Consultant for BioSense Webster, a J&J Co. Aortic stenosis background. Short history of TAVR
TRANSCATHETER AORTIC VALVE REPLACEMENT IN 2018: IS IT NOW THE STANDARD OF CARE? 22 ND ANNUAL COASTAL CARDIAC & VASCULAR CONFERENCE FEBRUARY 17, 2018 R. David Anderson, MD, MS, FACC, FSCAI Professor of
More informationFrailty: Challenges and Possible Solutions
Frailty: Challenges and Possible Solutions EMA Workshop: Ensuring safe and effective medicines for an ageing population Niccolò Marchionni Professor of Geriatrics University of Florence, Italy 22-23 March
More informationAtul Anand, MBChB, MRCP; Nicholas L. Mills, MBChB, PhD, FRCP, FESC BHF Centre for Cardiovascular Science, University of Edinburgh, UK
Original Article Heart Metab. (2018) 76:13-17 Aortic stenosis in the frail patient: maximizing the benefit of TAVI Atul Anand, MBChB, MRCP; Nicholas L. Mills, MBChB, PhD, FRCP, FESC BHF Centre for Cardiovascular
More informationIndication, Timing, Assessment and Update on TAVI
Indication, Timing, Assessment and Update on TAVI Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Starr- Edwards Mechanical
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter
More informationTranscatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients:
Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 1-Year Results from the SURTAVI Clinical Trial Nicolas M. Van
More informationPresented by Nicola Straiton (PhD Candidate) Sydney Nursing School. The University of Sydney Page 1
Health-Related Quality of Life and Functional Capacity Outcomes Post Transcatheter Aortic Valve Replacement (TAVR): A Systematic Review and Meta- Analysis Presented by Nicola Straiton (PhD Candidate) Sydney
More informationAppropriate Patient Selection or Healthcare Rationing? Lessons from Surgical Aortic Valve Replacement in The PARTNER I Trial Wilson Y.
Appropriate Patient Selection or Healthcare Rationing? Lessons from Surgical Aortic Valve Replacement in The PARTNER I Trial Wilson Y. Szeto, MD on behalf of The PARTNER Trial Investigators and The PARTNER
More informationValve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal
Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal I have nothing to disclose. Wide Spectrum Stable vs Decompensated NYHA II IV? Ejection
More informationStrokes After TAVR Reasons for Declining Frequency
Strokes After TAVR Reasons for Declining Frequency Samir Kapadia, MD Professor of Medicine Director, Cardiac Catheterization Laboratory Cleveland Clinic Disclosure NONE Second Generation Valves Newer
More informationEssential Support for a Structural Heart Program: The Valve and Structural Heart Clinic
Essential Support for a Structural Heart Program: The Valve and Structural Heart Clinic Vincent Varghese, DO, FACC, FSCAI Director, Interventional Cardiology Fellowship Program Deborah Heart and Lung Center
More informationFive-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial
Five-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators
More informationThe Role of TAVI in high-risk and normal-risk Patients
The Role of TAVI in high-risk and normal-risk Patients Joachim Schofer Hamburg University Cardiovascular Center and Department for percutaneous treatment of structural heart disease Albertinen Heart Center
More informationAortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV?
Aortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV? Samin K Sharma, MD, FACC, FSCAI Director Clinical & Interventional
More informationAortic stenosis in octogenarians and comorbidities. Constantinos Evdoridis, MD Elpis General Hospital, Athens
Aortic stenosis in octogenarians and comorbidities Constantinos Evdoridis, MD Elpis General Hospital, Athens Decision to operate according to age range European Heart Journal (2005) 26, 2714 2720 Fitness
More informationPreoperative Assessment Guidelines in the Elderly
Preoperative Assessment Guidelines in the Elderly How Are They Helping? Mark R. Katlic, M.D., M.M.M. Chairman, Department of Surgery Director, Center for Geriatric Surgery Sinai Hospital Baltimore, Maryland
More informationThe Korean version of the FRAIL scale: clinical feasibility and validity of assessing the frailty status of Korean elderly
ORIGINAL ARTICLE Korean J Intern Med 2016;31:594-600 The Korean version of the FRAIL scale: clinical feasibility and validity of assessing the frailty status of Korean elderly Hee-Won Jung 1,2, Hyun-Jung
More informationTAVI After PARTNER-2 : The Hamilton Approach
TAVI After PARTNER-2 : The Hamilton Approach James L. Velianou MD FRCPC Interventional Cardiology Hamilton General Hospital St Catharines General Hospital Associate Professor of Medicine McMaster University
More informationBelow is summarised some of the tools and papers that are worth looking at if you have an interest in the area.
What happens to the high risk patients who don t die? Perioperative SIG meeting PBLD Noosa 2015 Nicola Broadbent, Auckland, NZ In the process of writing this problem based learning discussion I have read
More informationPercutaneous Management of Severe AS in Octagenarians. Phillip Matsis FRACP FCSANZ Interventional Cardiologist Wakefield Heart Centre Wellington
Percutaneous Management of Severe AS in Octagenarians Phillip Matsis FRACP FCSANZ Interventional Cardiologist Wakefield Heart Centre Wellington May 2017 Outline Aetiology of AS Natural History of AS Assessment
More informationChairs: John Lainchbury & Andrew Aitken. Elderly/Frailty
Frailty Elderly/Frailty Ralph Stewart Chairs: John Lainchbury & Andrew Aitken Elderly/Frailty Ralph Stewart Green Lane Cardiovascular Service and Cardiovascular Research Unit Auckland City Hospital 1 What
More informationSystematic review on the predictive ability of frailty assessment measures in cardiac surgery
Interactive CardioVascular and Thoracic Surgery 24 (2017) 619 624 doi:10.1093/icvts/ivw374 Advance Access publication 9 January 2017 STATE-OF-THE-ART ADULT CARDIAC Cite this article as: Abdullahi YS, Athanasopoulos
More informationHow to Avoid Prosthesis-Patient Mismatch
How to Avoid Prosthesis-Patient Mismatch Philippe Pibarot, DVM, PhD, FACC, FAHA, FASE, FESC Canada Research Chair in Valvular Heart Diseases INSTITUT UNIVERSITAIRE DE CARDIOLOGIE ET DE PNEUMOLOGIE DE QUÉBEC
More informationOptions for my no option Patients Treating Heart Conditions Via a Tiny Catheter
Options for my no option Patients Treating Heart Conditions Via a Tiny Catheter Nirat Beohar, MD Associate Professor of Medicine Director Cardiac Catheterization Laboratory, Medical Director Structural
More informationTAVR y Enfermedad Coronaria. Mauricio G. Cohen, MD, FACC, FSCAI Director, Cardiac Catheterization Lab Associate Professor of Medicine
TAVR y Enfermedad Coronaria Mauricio G. Cohen, MD, FACC, FSCAI Director, Cardiac Catheterization Lab Associate Professor of Medicine CAD and AS Similar Pathological Processes CAD in TAVR Patients (n=390)
More informationSotirios N. Prapas, M.D., Ph.D, F.E.C.T.S.
CORONARY ARTERY REVASCULARIZATION WITH MILD AORTIC STENOSIS: STRATEGIES OF TREATMENT 9 th ANNUAL MEETING OF THE EAB SOCIETY, Pravets, Bulgaria, 2012 Sotirios N. Prapas, M.D., Ph.D, F.E.C.T.S. Director
More informationCARDIAC REHABILITATION AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION: A SINGLE CENTRE EXPERIENCE
ESC Congress 2011 27 Aug - 31 Aug 2011, Paris - France CARDIAC REHABILITATION AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION: A SINGLE CENTRE EXPERIENCE N.Russo, L.Compostella, T.Setzu, M.Napodano, L.Testolin,
More informationPost-TAVI Cerebral Embolisms and Potential Protection Means
Post-TAVI Cerebral Embolisms and Potential Protection Means Josep Rodés-Cabau, MD Quebec Heart & Lung Institute, Laval University Quebec City, Quebec, Canada EBR Marseille, May 2012 Conflict of Interest
More informationPERIOPERATIVE ANESTHETIC RISK IN THE GERIATRIC PATIENT
PERIOPERATIVE ANESTHETIC RISK IN THE GERIATRIC PATIENT Susan H. Noorily, M.D. Clinical Professor of Anesthesiology Medical Director University Preoperative Medicine Center IMPORTANCE Half of all currently
More informationThe Deconditioned Elderly Patient: Have We Been Getting it Wrong? By: Ernest Roy PT, DPT
The Deconditioned Elderly Patient: Have We Been Getting it Wrong? By: Ernest Roy PT, DPT The Debilitated Patient A review of outcomes for > 84,000 patients over 65 y/o revealed: Rate of functional recovery
More informationTAVI Versus Suturless Valve In Intermediate Risk Patients
TAVI Versus Suturless Valve In Intermediate Risk Patients Walid Abukhudair FRCSc President of Saudi Society for Cardiac Surgeons Head of Cardiac Surgery in KFAFH Background AS is the most frequent cardiac
More informationComorbidities in Multiple Myeloma
Comorbidities in Multiple Myeloma Michel Delforge, MD, PhD University Hospital Leuven Leuven, Belgium COMy, Bangkok 12 may 2014 Comy Meeting, Bangkok, 12 may 2014 Disclosures Advisory board: Janssen,
More information03/07/ Background. + High Risk Features Are Prevalent in Dialysis Patients
+ When Does Cardiovascular Disease Preclude Consideration of Renal Transplantation? Kul Aggarwal, MD, MRCP (UK), FACC Professor of Clinical Medicine Division of Cardiology University of Missouri & Chief,
More informationFEV1 predicts length of stay and in-hospital mortality in patients undergoing cardiac surgery
EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2010 FEV1 predicts length of stay and in-hospital mortality in patients undergoing cardiac surgery Nicholas L Mills, David A McAllister, Sarah Wild, John D MacLay,
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age
More informationNew York City Development of the Geriatric Collaborative
New York City - 2014 Development of the Geriatric Collaborative The Clinical Problem More than 50% persons age 65 years will have some surgical procedure in the remainder of his or her lifetime Outcome
More informationAortic Valve Practice Guidelines: What Has Changed and What You Need to Know
Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know James F. Burke, MD Program Director Cardiovascular Disease Fellowship Lankenau Medical Center Disclosure Dr. Burke has no conflicts
More informationTEE guided TAVR using BASILICA technique in patient with stenotic Freestyle aortic bioprosthesis
TEE guided TAVR using BASILICA technique in patient with stenotic Freestyle aortic bioprosthesis Zuyue Wang MD Associate professor, Georgetown University School of Medicine MedStar Heart and Vascular Institute
More informationFRAILTY SYNDROME. dr. Rose Dinda Martini, Sp.PD, K-Ger
FRAILTY SYNDROME dr. Rose Dinda Martini, Sp.PD, K-Ger Geriatric Division, Internal Medicine Department M. Djamil Hospital Padang Faculty of Medicine, Andalas University, 2018 Medical syndrome Multiple
More information4/26/2012. Laura Grooms, MD Assistant Professor Geriatric Medicine Department of Family and Geriatric Medicine University of Louisville April 20, 2012
Laura Grooms, MD Assistant Professor Geriatric Medicine Department of Family and Geriatric Medicine University of Louisville April 20, 2012 Laura Grooms, MD Assistant Professor Geriatric Medicine Department
More informationChapter 4: Cardiovascular Disease in Patients with CKD
Chapter 4: Cardiovascular Disease in Patients with CKD The prevalence of cardiovascular disease (CVD) was 65.8% among patients aged 66 and older who had chronic kidney disease (CKD), compared to 31.9%
More informationAssessing the utility of simple measures of frailty in older hospital-based cardiology patients. by Yong Yong Tew (medical student)
Assessing the utility of simple measures of frailty in older hospital-based cardiology patients by Yong Yong Tew (medical student) Declaration No conflict of interest. Ethical considerations Reviewed and
More informationProf. Dr. Thomas Walther. TAVI in ascending aorta / aortic root dilatation
Prof. Dr. Thomas Walther TAVI in ascending aorta / aortic root dilatation nn AorticStenosis - Guidelines TAVI and aortic aneurysm? Few data published. EJCTS 2014;46:228-33 TAVI and aortic aneurysm? Few
More informationSurgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea
Surgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea Contents Decision making in surgical AVR in old age Clinical results of AVR with tissue valve Impact of 19mm
More informationAortic Stenosis: Background
Transcatheter Aortic Valve Replacement in Low Surgical Risk Patients Barry George, MD The Ohio State University Structural Heart Disease Course May 19 th, 2017 Aortic Stenosis: Background Severe Symptomatic
More informationRisk assessment. Heart Team Evaluation
Chapter 8: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines. Iliana S. Hurtado Rendón, MD, Peter Bittenbender, MD, Justin M. Dunn, MD, MPH, Michael S. Firstenberg, MD Akron
More informationFrailty: from Academic Definition to Clinical Applicability
Frailty: from Academic Definition to Clinical Applicability Associate Professor Ruth E. Hubbard October 26 th 2018 Objectives 1. Describe the development of frailty as a concept 2. Provide an overview
More informationWhen Should We Consider TAVI. (Surgeon s Viewpoint)? Pyowon Park Samsung Medical Center Seoul, Korea
When Should We Consider TAVI Procedure in Korea (Surgeon s Viewpoint)? Pyowon Park Samsung Medical Center Seoul, Korea Aortic Stenosis in Korea Rapidly increasing valve disease in Korea Still low incidence
More informationCIPG Transcatheter Aortic Valve Replacement- When Is Less, More?
CIPG 2013 Transcatheter Aortic Valve Replacement- When Is Less, More? James D. Rossen, M.D. Professor of Medicine and Neurosurgery Director, Cardiac Catheterization Laboratory and Interventional Cardiology
More informationTAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con
TAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con Dimitrios C. Angouras, MD, FETCS Associate Professor of Cardiac Surgery National and Kapodistrian University of Athens,
More informationA Study of relationship between frailty and physical performance in elderly women
Original Article Journal of Exercise Rehabilitation 2015;11(4):215-219 A Study of relationship between frailty and physical performance in elderly women Bog Ja Jeoung 1, *, Yang Chool Lee 2 1 Department
More informationLorraine Montoya, BSN, MAdEd APN / Coordinator TAVI Program. 7 April
Using Frailty Measurement to Assist With Patient Assessment and Discharge Planning in Patients Undergoing Transcatheter Aortic Valve Implant Results of a Pilot Project Lorraine Montoya, BSN, MAdEd APN
More informationMitral Valve Disease, When to Intervene
Mitral Valve Disease, When to Intervene Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Current ACC/AHA guideline Stages
More informationJosep Rodés-Cabau, MD, on behalf of the ARTE investigators
Versus Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve The ARTE Randomized Clinical Trial Josep Rodés-Cabau, MD, on behalf
More informationAortic Valve Stenosis and TAVR: Putting it all together.
Aortic Valve Stenosis and TAVR: Putting it all together. Maria L. Held, MSN CNS Valve Clinic Coordinator at The Cleveland Clinic Alliance of Cardiovascular Professionals April 14 th, 2018 Brief Anatomy
More informationTAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?
TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? Elaine E. Tseng, MD and Marlene Grenon, MD Department of Surgery Divisions of Adult Cardiothoracic and Vascular and Endovascular
More informationStrokes After TAVR. Ioannis Iakovou, MD, PhD. Interventional Cardiology Onassis Cardiac Surgery Center
Strokes After TAVR Ioannis Iakovou, MD, PhD Interventional Cardiology Onassis Cardiac Surgery Center Strokes After TAVR How common is stroke after TAVR Is it increasing? Is it more with TF vs TA? Is it
More informationWelcome 17 Michigan TAVR Participating Hospitals!
Welcome 17 Michigan TAVR Participating Hospitals! 1 MICHIGAN TAVR BRIEF OVERVIEW HOW AND WHY PRE-TAVR IMAGING EVALUATION AND THE TVT Michael Grossman, MD Co-Director, BMC2 Coordinating Center Why Michigan
More informationTranscatheter Aortic-Valve Implantation for Aortic Stenosis
Transcatheter Aortic-Valve Implantation for Aortic Stenosis Policy Number: 7.01.132 Last Review: 6/2018 Origination: 2/2012 Next Review: 2/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC)
More informationAortic Stenosis in the Elderly: Difficulties for the Clinician. Are Symptoms Due to Aortic Stenosis?
Aortic Stenosis in the Elderly: Difficulties for the Clinician Are Symptoms Due to Aortic Stenosis? Raphael Rosenhek Department of Cardiology Medical University of Vienna No disclosure European Society
More informationManagement of High-Risk Patients With Aortic Stenosis and Coronary Artery Disease
Management of High-Risk Patients With Aortic Stenosis and Coronary Artery Disease Daniel Wendt, MD, Philipp Kahlert, MD, Tim Lenze, Markus Neuhäuser, MD, Vivien Price, Thomas Konorza, MD, Raimund Erbel,
More informationTranscatheter Aortic Valve Replacement TAVR
Transcatheter Aortic Valve Replacement TAVR Paul Gordon, MD Associate Prof of Medicine, Brown University Director, Cardiac Catheterization Laboratory The Miriam Hospital Disclosures: none 100 Symptomatic
More informationAssessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington
Assessing Cardiac Risk in Noncardiac Surgery Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington Disclosure None. I have no conflicts of interest, financial or otherwise. CME
More informationFRAILTY AND COGNITION IN THE ASSESSMENT OF VASCULAR SUGERY PATIENTS WHY WHY DISCLOSURES. INDIVIDUAL None. INSTITUTIONAL Cook, Inc
DISCLOSURES FRAILTY AND COGNITION IN THE ASSESSMENT OF VASCULAR SUGERY PATIENTS INDIVIDUAL None INSTITUTIONAL Cook, Inc Not discussing off-label use of anything WHY WHY Frailty increases with age Frailty
More informationTAVR and Cardiac Surgeons
TAVR and Cardiac Surgeons TAVR and Cardiac Surgeons Ragheb Hasan Consultant and Clinical Lead Cardiothoracic Surgeon Manchester Royal Infirmary, Oxford Road, Manchester UK Aortic Stenosis Is A Growing
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Transcatheter Aortic Valve Implantation for Aortic Stenosis Page 1 of 37 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Transcatheter Aortic Valve Implantation
More informationKidney Transplant in the Elderly. Robert Santella, M.D., F.A.C.P.
Kidney Transplant in the Elderly! Robert Santella, M.D., F.A.C.P. Incident Rate of ESRD by Age Age 75+ 65-74 From US Renal Data System, 2012 Should there be an age limit? Various guidelines: Canadian,
More informationChapter 4: Cardiovascular Disease in Patients With CKD
Chapter 4: Cardiovascular Disease in Patients With CKD The prevalence of cardiovascular disease is 68.8% among patients aged 66 and older who have CKD, compared to 34.1% among those who do not have CKD
More informationGeriatric screening tools in older patients with cancer
Geriatric screening tools in older patients with cancer Pr. Elena Paillaud Henri Mondor hospital, Créteil, France University Paris-Est Créteil CONFLICT OF INTEREST DISCLOSURE I have the following potential
More informationThe FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation
The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation Susheel Kodali, MD Director, Structural Heart & Valve
More informationOutcome of elderly patients with severe but asymptomatic aortic stenosis
Outcome of elderly patients with severe but asymptomatic aortic stenosis Robert Zilberszac, Harald Gabriel, Gerald Maurer, Raphael Rosenhek Department of Cardiology Medical University of Vienna ESC Congress
More informationBiomedical versus BioPsychosocial Model of Frailty
Bologna 22 March 2016 Biomedical versus BioPsychosocial Model of Frailty Marcello Maggio MD PhD Department of Clinical and Experimental Medicine University of Parma Geriatric-Rehabilitation Department
More informationThe Elusive Frailty Formula: Shining the geriatric light on the 1-5% Dr John Puxty
The Elusive Frailty Formula: Shining the geriatric light on the 1-5% Dr John Puxty puxtyj@providencecare.ca Health Care use is not uniform by Seniors How common is Frailty? Approximately10% of all individuals
More informationRevascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease
Impact of Angiographic Complete Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Young-Hak Kim, Duk-Woo Park, Jong-Young Lee, Won-Jang
More informationValvular Heart Disease Transcatheter Valve Therapies. October 2016 Brian Whisenant MD
Valvular Heart Disease Transcatheter Valve Therapies October 2016 Brian Whisenant MD Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement
More informationModulate the prevention stategy according to the level of frailty. Prof Leocadio Rodríguez Mañas Hospital Universitario de Getafe
Modulate the prevention stategy according to the level of frailty Prof Leocadio Rodríguez Mañas Hospital Universitario de Getafe CONFLICT OF INTEREST DISCLOSURE I have no potential conflict of interest
More information22/06/2017. Oxford City. Transcatheter aortic valve replacement 2017 guidelines. 1. First time I have heard about it. 2.
Oxford City Transcatheter aortic valve replacement 2017 guidelines Monday 19 th June Jim Newton Oxford Oxford University Hospitals NHS FT How familiar are you with TAVR? 1. First time I have heard about
More informationFor the SURTAVI Investigators
Neurological complications after transcatheter aortic valve implantation with a self-expanding bioprosthesis or surgical aortic valve replacement in patients at intermediate-risk for surgery A. Pieter
More informationTAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central
TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University 1 Disclosure Chiesi Pharma- Consultant
More informationMaurizio D Amico M.D.
TAVI BEST CANDIDATE AND OPTIMIZED LONG TERM FOLLOW-UP Maurizio D Amico M.D. Dipartimento Cardiovascolare e Toracico Città della Salute e della Scienza, Turin Italy Regional Guidelines for TAVI implantation
More informationEvaluation of fragility and factors influencing falls in nursing homes. Dr Marie-Laure Seux Geriatrics Broca Hospital May 2013
Evaluation of fragility and factors influencing falls in nursing homes Dr Marie-Laure Seux Geriatrics Broca Hospital May 2013 Epidemiological data Among the over 65s: 1/3 present at least one fall per
More informationTranscatheter Aortic-Valve Implantation for Aortic Stenosis
Transcatheter Aortic-Valve Implantation for Aortic Stenosis Policy Number: 7.01.132 Last Review: 2/2019 Origination: 2/2012 Next Review: 2/2020 Policy Blue Cross and Blue Shield of Kansas City (Blue KC)
More informationSaudi Heart Association. Raising Standards through Education and Training
Saudi Heart Association Raising Standards through Education and Training 25th Annual Meeting EACTS Lisbon, Oc ctober 2011 WWW EA WWW. ACTS ORG ACTS.ORG Clinical decision making in case of Aortic valve
More informationValvular Guidelines: The Past, the Present, the Future
Valvular Guidelines: The Past, the Present, the Future Robert O. Bonow, MD, MS Northwestern University Feinberg School of Medicine Bluhm Cardiovascular Institute Northwestern Memorial Hospital Editor-in-Chief,
More informationTranscatheter aortic valve replacement is considered investigational for all other indications.
Medical Policy Original Policy Date: March 30, 2012 Effective Date: July 1, 2018 Section: 7.0 Surgery Page: Page 1 of 33 Policy Statement Transcatheter aortic valve replacement with an U.S. Food and Drug
More informationTranscatheter Aortic Valve Replacement
Transcatheter Aortic Valve Replacement Jesse Jorgensen, MD Medical Director, Cardiac Catheterization Laboratory Greenville Health System Greenville, South Carolina, USA January 30, 2016 Aortic Stenosis
More informationTAVR in patients with. End-Stage CKD or in Renal Replacement Therapy:
TAVR in patients with End-Stage CKD or in Renal Replacement Therapy: Special Considerations and Prevention of early Valve Failure Antonios Chalapas, MD, PhD, FESC THV & Hygeia Hospital Heart Team Athens,
More informationUnderstanding the guidelines for Interventions in MR. Ali AlMasood
Understanding the guidelines for Interventions in MR Ali AlMasood Mitral regurgitation The most diverse from all acquired valve diseases About 50% of patients with an LVEF 35 percent had moderate to severe
More informationVariability in Antithrombotic Therapy Regimens Peri-TAVR: A Single Academic Center Experience
DOI 10.1007/s40119-015-0050-2 BRIEF REPORT Variability in Antithrombotic Therapy Regimens Peri-TAVR: A Single Academic Center Experience Jeffrey E. Rossi. Andrew Noll. Brian Bergmark. James M. McCabe.
More informationIschemic Mitral Valve Disease: Repair, Replace or Ignore?
Ischemic Mitral Valve Disease: Repair, Replace or Ignore? Fabio B. Jatene Full Professor of Cardiovascular Surgery, Medical School, University of São Paulo, Brazil DISCLOSURE I have no financial relationship
More informationHealth Status after Transcatheter Mitral- Valve Repair in Patients with Heart Failure and Secondary Mitral Regurgitation: Results from the COAPT Trial
Health Status after Transcatheter Mitral- Valve Repair in Patients with Heart Failure and Secondary Mitral Regurgitation: Results from the COAPT Trial Suzanne V. Arnold, MD, MHA Saint Luke s Mid America
More information